Rani Therapeutics Holdings Inc (RANI) - Total Assets
Based on the latest financial reports, Rani Therapeutics Holdings Inc (RANI) holds total assets worth $10.14 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check Rani Therapeutics Holdings Inc (RANI) total reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Rani Therapeutics Holdings Inc - Total Assets Trend (2019–2024)
This chart illustrates how Rani Therapeutics Holdings Inc's total assets have evolved over time, based on quarterly financial data. Check Rani Therapeutics Holdings Inc tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Rani Therapeutics Holdings Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Rani Therapeutics Holdings Inc's total assets of $10.14 Million consist of 81.2% current assets and 18.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 10.3% |
| Accounts Receivable | $428.00K | 1.2% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how Rani Therapeutics Holdings Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Rani Therapeutics Holdings Inc market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Rani Therapeutics Holdings Inc's current assets represent 81.2% of total assets in 2024, an increase from 73.6% in 2019.
- Cash Position: Cash and equivalents constituted 10.3% of total assets in 2024, down from 71.8% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is accounts receivable at 1.2% of total assets.
Rani Therapeutics Holdings Inc Competitors by Total Assets
Key competitors of Rani Therapeutics Holdings Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
|
USA | $4.40K |
|
Krystal Biotech Inc
NASDAQ:KRYS
|
USA | $1.40 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
Rani Therapeutics Holdings Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.26 | 1.60 | 14.12 |
| Quick Ratio | 0.26 | 1.60 | 14.12 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-14.19 Million | $12.16 Million | $69.64 Million |
Rani Therapeutics Holdings Inc - Advanced Valuation Insights
This section examines the relationship between Rani Therapeutics Holdings Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 23.87 |
| Latest Market Cap to Assets Ratio | 2.04 |
| Asset Growth Rate (YoY) | -36.7% |
| Total Assets | $36.63 Million |
| Market Capitalization | $74.65 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Rani Therapeutics Holdings Inc's assets at a significant premium (2.04x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Rani Therapeutics Holdings Inc's assets decreased by 36.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Rani Therapeutics Holdings Inc (2019–2024)
The table below shows the annual total assets of Rani Therapeutics Holdings Inc from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $36.63 Million | -36.75% |
| 2023-12-31 | $57.92 Million | -46.39% |
| 2022-12-31 | $108.03 Million | -13.03% |
| 2021-12-31 | $124.21 Million | +56.40% |
| 2020-12-31 | $79.42 Million | +244.95% |
| 2019-12-31 | $23.02 Million | -- |
About Rani Therapeutics Holdings Inc
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug subst… Read more